Create a narrative

Mirum Pharmaceuticals Community

NasdaqGM:MIRM Community

1 Narratives written by author
0 Comments on narratives written by author
18 Fair Values set on narratives written by author

Mirum Pharmaceuticals

AN

AnalystConsensusTarget

AnalystConsensusTarget

Consensus Narrative from 11 Analysts

Genetic Testing And International Expansion Will Broaden Rare Disease Markets

Key Takeaways Broader patient identification, international expansion, and supportive reimbursement environments are driving sustained revenue growth and improving margins for Mirum's portfolio. Advancing late-stage pipeline programs and leveraging precision medicine support future product expansion, revenue diversification, and long-term earnings acceleration.

US$77.20

FV

16.2% undervalued

22.78%

Revenue growth p.a.

0

0

13

Updated